SCHEDULE 13G/A: BlackRock Discloses 7.8% Stake in Agios Pharmaceuticals
Institutional Ownership Update
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.8% of Agios Pharmaceuticals Inc.'s common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 4,513,170 shares of Agios Pharmaceuticals Inc. common stock.
- This stake represents 7.8% of the total outstanding common stock of Agios Pharmaceuticals Inc.
- BlackRock holds sole voting power over 4,375,383 shares and sole dispositive power over 4,513,170 shares.
- The filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported passive investment position.
- The filing was made under Rule 13d-1(b), signifying that BlackRock is a qualified institutional investor holding the securities in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership by an institutional investor and does not contain qualitative information to assess sentiment beyond the fact of a significant holding.
Positives
- A major institutional investor, BlackRock, holds a significant 7.8% stake in Agios Pharmaceuticals Inc., which can be interpreted as a sign of confidence in the company.
- The filing is an amendment, suggesting a continued or updated passive investment by BlackRock.
Negatives
- No specific negative information about Agios Pharmaceuticals Inc. is disclosed in this ownership filing.
Risks
- This Schedule 13G filing does not detail specific operational or financial risks related to Agios Pharmaceuticals Inc. It is solely a disclosure of beneficial ownership by an institutional investor.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and potentially provide stability.
- Management: Awareness of a large, passive institutional investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution for the Power of Attorney granted by BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 07/17/2025 | Date of filing of this statement. |
Keywords
BlackRock, Agios Pharmaceuticals, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Pharmaceutical, Biotech, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.